In lung cancer, mutations or deletions of SETD2 lead to decreased H3K36me3 levels, triggering replication stress, DNA mismatch repair defects, and genomic instability, thereby promoting tumor heterogeneity and drug resistance (202). This evidence concerns the gene SETD2 and lung carcinoma.